On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...